Cost of illness and economic burden of chronic lymphocytic leukemia

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Blankart, Carl Rudolf ^a   Koch, Taika ^a   Linder, Roland ^b   Verheyen, Frank ^b   Schreyögg, Jonas ^a   Stargardt, Tom ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b WINEG Scientific Institute of the Techniker Krankenkasse (TK)   (Germany)

Author keywords

Administrative data; Case control design; CLL; Economic evaluation; Elixhauser comorbidity groups; Routine data

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; COST OF ILLNESS; DIAGNOSIS RELATED GROUP; DRUG COST; FEMALE; FUNDING; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOSPITAL COST; HOSPITALIZATION; HUMAN; INVESTMENT; MAJOR CLINICAL STUDY; MALE;

CASE-CONTROL STUDIES; COST OF ILLNESS; FEMALE; GERMANY; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE;

EID: 84873963736     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-32     Document Type: Article

References (33)

1. When and How to Treat Chronic Lymphocytic Leukemia. Dighiero G, Binet J-L, N Engl J Med 2000 343 1799 1801 10.1056/NEJM200012143432410 11114321
2. Orphanet, Prevalence of rare diseases: Bibliographic data Paris: Orphanet 2011
3. National Cancer Institute, SEER cancer statistics Bethesda: National Cancer Institute 2008
4. Chronische lymphatische Leukämie/lymphoplasmozytoides Lymphom. Hallek M, Emmerich B, Kompendium Internistische Onkologie Berlin: Springer, Schmoll H-J, Höffken K, Possinger K, 2006 2845 2886
5. Chronic Lymphocytic Leukemia: Economic Burden and Quality of Life: Literature Review. Stephens JM, Gramegna P, Laskin B, Botteman MF, Pashos CL, Am J Ther 2005 12 460 466 10.1097/01.mjt.0000104489.93653.0f 16148431 (Pubitemid 41445143)
6. Zulassung und Erstattung von Orphan Drugs im internationalen Vergleich. Roll K, Stargardt T, Schreyögg J, Gesundheitswesen 2011 73 504,514
7. The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML. Redaelli A, Stephens JM, Laskin BL, Pashos CL, Botteman MF, Expert Rev Anticancer Ther 2003 3 311 329 10.1586/14737140.3.3.311 12820775 (Pubitemid 36752619)
8. Models for Longitudinal Data: A Generalized Estimating Equation Approach. Zeger SL, Liang K-Y, Albert PS, Biometrics 1988 44 1049 1060 10.2307/2531734 3233245 (Pubitemid 19026037)
9. Bootstrap Methods: Another Look at the Jackknife. Efron B, Ann Stat 1979 7 1 26 10.1214/aos/1176344552
10. Bundesvereinigung K, Statistische Basisdaten zur vertragszahnä rztlichen Versorgung Köln: Kassenzahnärztliche Bundesvereinigung 2011
11. Bundesamt S, Gesundheitsausgabenrechnung Bonn: Statistisches Bundesamt 2008
12. How to Calculate Indirect Costs in Economic Evaluations. Liljas B, PharmacoEconomics 1998 13 1 7 10.2165/00019053-199813010-00001 10175982 (Pubitemid 28033986)
13. Statistisches Bundesamt, Entwicklung der Bruttoverdienste Wiesbaden: Statistisches Bundesamt 2007 8
14. Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation. Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B, Gesundheitswesen 2005 67 736 746 10.1055/s-2005-858698 16235143 (Pubitemid 41604934)
15. Likelihood Ratio Tests for Model Selection and Non-Nested Hypotheses. Vuong QH, Econometrica 1989 57 307 333 10.2307/1912557
16. Comorbidity measures for use with administrative data. Elixhauser A, Steiner C, Harris DR, Coffey RM, Med Care 1998 36 8 27 10.1097/00005650- 199801000-00004 9431328 (Pubitemid 128456396)
17. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA, Med Care 2005 43 1130 1139 10.1097/01.mlr.0000182534.19832.83 16224307 (Pubitemid 41587600)
18. Infection and Immunity in Chronic Lymphocytic Leukemia. Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP, Mayo Clin Proc 2000 75 1039 1054 10.4065/75.10.1039 11040852
19. Cost of illness of malignant lymphoma in Germany. Reis A, Ihle P, Paulus U, Ferber LV, Diehl V, Walshe R, Eur J Cancer Care (Engl) 2006 15 379 385 10.1111/j.1365-2354.2006.00676.x (Pubitemid 44359402)
20. Cost-of-illness studies: a review of current methods. Akobundu E, Ju J, Blatt L, Mullins CD, PharmacoEconomics 2006 24 869 890 10.2165/00019053- 200624090-00005 16942122 (Pubitemid 44338298)
21. Genetic Susceptibility Variants for Chronic Lymphocytic Leukemia. Slager SL, Goldin LR, Strom SS, Lanasa MC, Spector LG, Rassenti L, Leis JF, Camp NJ, Kay NE, Vachon CM, et al. Cancer Epidemiol Biomarkers Prev 2010 19 1098 1102 10.1158/1055-9965.EPI-09-1217 20332261
22. Cost-of-illness studies: a guide to critical evaluation. Larg A, Moss JR, PharmacoEconomics 2011 29 653 671 10.2165/11588380-000000000-00000 21604822
23. World Health Organization, WHO guide to identifying the economic consequences of disease and injury Geneva: World Health Organization 2009
24. Methods to determine reimbursement rates for diagnosis related groups (DRG): A comparison of nine European countries. Schreyögg J, Stargardt T, Tiemann O, Busse R, Health Care Manag Sci 2006 9 215 223 10.1007/s10729-006- 9040-1 17016927 (Pubitemid 44198206)
25. Roche, Annual Report 2001 Basel: F. Hoffmann-La Roche Ltd 2001
26. Roche, Annual Report 2011 Basel: F. Hoffmann-La Roche Ltd 2011
27. The cost burden of diabetes mellitus: the evidence from Germany-the CoDiM Study. Köster I, von Ferber L, Ihle P, Schubert I, Hauner H, Diabetologia 2006 49 1498 1504 10.1007/s00125-006-0277-5 16752168 (Pubitemid 43848085)
28. Economic burden of cardiovascular diseases in the enlarged European Union. Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M, Eur Heart J 2006 27 1610 1619 10.1093/eurheartj/ehi733 16495286 (Pubitemid 43954923)
29. Prevalence and Costs of Chronic Conditions in the VA Health Care System. Yu W, Ravelo A, Wagner TH, Phibbs CS, Bhandari A, Chen S, Barnett PG, Med Care Res Rev 2003 60 146S 167S 10.1177/1077558703257000 15095551 (Pubitemid 36993500)
30. Health services research based on routine data generated by the SHI, Potential uses of health insurance fund data in health services research. Schubert I, Koster I, Kupper-Nybelen J, Ihle P, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008 51 1095 1105 10.1007/s00103-008- 0644-0 18985403
31. Ageing and health-care expenditure: the red herring argument revisited. Seshamani M, Gray A, Health Econ 2004 13 303 314 10.1002/hec.826 15067669 (Pubitemid 38477075)
32. Uncertainty Assessment of Input Parameters for Economic Evaluation: Gauss's Error Propagation, an Alternative to Established Methods. Stollenwerk B, Stock S, Siebert U, Lauterbach KW, Holle R, Med Decis Making 2010 30 304 313 10.1177/0272989X09347015 19815659
33. The risk of upcoding in casemix systems: A comparative study. Steinbusch PJM, Oostenbrink JB, Zuurbier JJ, Schaepkens FJM, Health Pol 2007 81 289 299 10.1016/j.healthpol.2006.06.002 (Pubitemid 46437415)